登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07771881,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or pathologically confirmed breast cancer.
入选标准第 3 条
Nadir platelet count <50×10⁹/L in the previous treatment cycle; OR nadir platelet count ≥50×10⁹/L but <75×10⁹/L in the previous chemotherapy cycle, plus at least one high-risk factor for bleeding as defined in the relevant guideline.
入选标准第 4 条
Receipt of romiplostim within 2 to 3 weeks prior to study drug administration;
排除标准第 9 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
入选标准第 8 条
Platelet count >100×10⁹/L at screening.
入选标准第 5 条
Significantly abnormal hepatic function: for patients without hepatic metastasis, ALT/AST >3×ULN and TBIL >3×ULN; for patients with hepatic metastasis, ALT/AST ≥5×ULN and TBIL ≥5×ULN;
排除标准第 7 条
Renal function abnormality: serum creatinine ≥1.5×ULN or eGFR ≤60 mL/min (by Cockcroft-Gault formula);
排除标准第 8 条
HIV infection;
排除标准第 11 条
Pregnant or lactating women;
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07771881,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Signed informed consent form. Age 18 to 75 years, either sex. Histologically or pathologically confirmed breast cancer. Nadir platelet count <50×10⁹/L in the previous treatment cycle; OR nadir platelet count ≥50×10⁹/L but <75×10⁹/L in the previous chemotherapy cycle, plus at least one high-risk factor for bleeding as defined in the relevant guideline. Platelet count >100×10⁹/L at screening. No prior exposure to romiplostim/romiplostim N01. Prior receipt of one or more antineoplastic therapies, including but not limited to chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Life expectancy of ≥12 weeks.排除标准:Exclusion Criteria:
Concomitant hematologic disorders; Prior radiation therapy to long bones or flat bones, or currently receiving/planned to receive radiation therapy (local radiation to the breast is permitted); Serious cardiac clinical symptoms or diseases within 6 months prior to screening; Thrombotic predisposition or currently receiving thrombolytic and/or anticoagulant therapy; Clinically significant bleeding symptoms within 2 weeks prior to screening, or definitive clinical manifestations of bleeding tendency; Complications requiring emergency treatment, such as superior vena cava syndrome or spinal cord compression; Significantly abnormal hepatic function: for patients without hepatic metastasis, ALT/AST >3×ULN and TBIL >3×ULN; for patients with hepatic metastasis, ALT/AST ≥5×ULN and TBIL ≥5×ULN; Renal function abnormality: serum creatinine ≥1.5×ULN or eGFR ≤60 mL/min (by Cockcroft-Gault formula); Receipt of romiplostim within 2 to 3 weeks prior to study drug administration; Known or suspected hypersensitivity or intolerance to romiplostim N01 or its excipients (including cellulose-lactose, low-substituted hydroxypropyl cellulose, and magnesium stearate); HIV infection; Participation in any other clinical study of an investigational drug or device within 3 months prior to screening; Pregnant or lactating women; Any other condition that, in the investigator's opinion, may affect study results or lead to premature discontinuation of the study.
引自 ClinicalTrials.gov, NCT07771881, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07771881,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。